Q1 FY27 saw 8% revenue growth to $105.4B and 20% adjusted EPS growth to $9.93, with strong performance in Oncology & Multispecialty and Prescription Technology Solutions. FY27 adjusted EPS guidance was raised to $44.20–$45.00, and $2.5B in share repurchases were completed.Original document: McKesso…
Q1 FY27 saw 8% revenue growth to $105.4B and 20% adjusted EPS growth to $9.93, with strong performance in Oncology & Multispecialty and Prescription Technology Solutions. FY27 adjusted EPS guidance was raised to $44.20–$45.00, and $2.5B in share repurchases were completed.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
